GLP1R and Parkinson disease: Interestingly, the prevalence of PD was decreased in T2DM patients who have been prescribed antidiabetic drugs such as GLP-1 receptor agonists or dipeptidyl peptidase IV (DPP-IV) inhibitors, suggesting a possible neuroprotective effect of these agents [6,7].